Introduction to Advanced Burn Management

Modern burn management has shifted significantly with the introduction of enzymatic debridement. Specifically, the ENGAGE protocol burn care strategy utilizes NexoBrid® to provide selective tissue-sparing benefits. While NexoBrid® effectively removes eschar, the surgical timing for subsequent interventions often varies. Researchers recently evaluated a structured algorithm to bridge this gap, focusing on clinical efficiency and patient recovery.

Clinical Efficacy of the ENGAGE Protocol Burn Care

The ENGAGE protocol (ENzymatic debridement with NexoBrid®, followed by Grafting After Graded early Excision) integrates enzymatic treatment with a scheduled day-7 reassessment. This before-and-after observational study compared standard management to this new structured approach. Notably, the group receiving the ENGAGE protocol achieved a significantly shorter length of hospital stay. Patients in this group spent an average of 24 days in the hospital, compared to 32 days in the standard group. This 25% reduction in stay highlights the protocol\'s ability to streamline recovery. Furthermore, mortality rates and autologous grafting requirements remained comparable between both groups. Therefore, the protocol improves efficiency without compromising patient safety.

Surgical Dynamics and Targeted Intervention

Interestingly, the number of surgical procedures per patient was higher in the ENGAGE group. This increase reflects the planned, biologically guided excision rather than increased morbidity. By performing early, targeted interventions after enzymatic debridement, surgeons can optimize the wound bed more effectively. Consequently, this structured refinement offers a reliable path for modern burn units to improve bed turnover and resource allocation. For clinicians in India, where burn centers often face high patient volumes, such protocols are essential for enhancing care delivery.

Frequently Asked Questions

What is the primary benefit of the ENGAGE protocol?

The primary benefit is a significant reduction in the length of hospital stay. By utilizing a day-7 reassessment and selective excision, the protocol shortens recovery time by approximately eight days without increasing mortality or grafting rates.

Does the ENGAGE protocol increase the risk of surgery?

While the number of surgical procedures per patient is higher, these are planned interventions meant for wound optimization. The study found no increase in morbidity or grafting rates, suggesting that the additional procedures are beneficial rather than harmful.

Who should consider implementing this protocol?

Burn surgeons and critical care specialists managing adult burn patients treated with enzymatic debridement should consider this structured algorithm to improve clinical outcomes and hospital efficiency.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. The information provided is based on recent clinical studies and may not apply to all patient scenarios. Refer to the latest local and national guidelines for clinical practice.

References

1. Lombardo GAG et al. The ENGAGE Protocol: ENzymatic debridement with NexoBrid® Followed by Grafting After Graded early Excision - A Retrospective Cohort Study. J Burn Care Res. 2026 Feb 20. doi: undefined. PMID: 41717791.


2. Hirche C, et al. Eschar removal by bromelain based enzymatic debridement (NexoBrid®) in burns: European consensus guidelines update. Burns. 2020;46(4):782-796.


3. Rosenberg L, et al. A novel rapid and selective enzymatic debridement agent for burn wound management: A multi-center RCT. Burns. 2014;40(3):466-474.